Literature DB >> 22733242

[Cholestatic pruritus : new insights into pathophysiology and current treatment].

A E Kremer1, R P J Oude Elferink, U Beuers.   

Abstract

Pruritus is a common symptom of hepatobiliary disorders and may considerably diminish quality of life. Cholestatic pruritus exerts a circadian rhythm and is typically most severe in the evening hours and early at night. Itching is reported often to be most intense at the palms and the soles, but may also be generalized. The pathophysiological mechanisms of cholestatic pruritus have not been completely clarified. In the past, bile salts, histamine, progesterone metabolites and opioids have been discussed as potential causal substances; a correlation with itch intensity could never be proven. The enzyme autotaxin, which releases lysophosphatidic acid, has recently been identified as potential cholestatic pruritogen. Treatment aims to bind pruritogens in the gut lumen by resins such as cholestyramine, to modulate pruritogen metabolism by rifampicin and to influence central itch signaling by µ-opioid antagonists and selective serotonin re-uptake inhibitors. In cases of refractory pruritus experimental treatment options such as UV-therapy, extracorporeal albumin dialysis and nasobiliary drainage may be considered.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22733242     DOI: 10.1007/s00105-011-2321-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  28 in total

Review 1.  Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis.

Authors:  E A Jones; N V Bergasa
Journal:  Can J Gastroenterol       Date:  2000-01       Impact factor: 3.522

2.  Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis.

Authors:  Ulrich Beuers; Guido Gerken; Thomas Pusl
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

3.  EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

Authors: 
Journal:  J Hepatol       Date:  2009-06-06       Impact factor: 25.083

4.  Raised histamine concentrations in chronic cholestatic liver disease.

Authors:  S D Gittlen; E S Schulman; W C Maddrey
Journal:  Gut       Date:  1990-01       Impact factor: 23.059

5.  The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial.

Authors:  Edith M M Kuiper; Karel J van Erpecum; Ulrich Beuers; Bettina E Hansen; H Bing Thio; Robert A de Man; Harry L A Janssen; Henk R van Buuren
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

6.  Intrahepatic cholestasis of pregnancy: Amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine.

Authors:  Anna Glantz; Sarah-Jayne Reilly; Lisbet Benthin; Frank Lammert; Lars-Ake Mattsson; Hanns-Ulrich Marschall
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

7.  PRURITUS AND JAUNDICE.

Authors:  N T MCPHEDRAN; R D HENDERSON
Journal:  Can Med Assoc J       Date:  1965-06-12       Impact factor: 8.262

8.  Endogenous opioid-mediated antinociception in cholestatic mice is peripherally, not centrally, mediated.

Authors:  Lisa Nelson; Nathalie Vergnolle; Charlotte D'Mello; Kevin Chapman; Tai Le; Mark G Swain
Journal:  J Hepatol       Date:  2005-12-27       Impact factor: 25.083

9.  Serum bile acids in primary biliary cirrhosis.

Authors:  G M Murphy; A Ross; B H Billing
Journal:  Gut       Date:  1972-03       Impact factor: 23.059

Review 10.  Itching after epidural and spinal opiates.

Authors:  J C Ballantyne; A B Loach; D B Carr
Journal:  Pain       Date:  1988-05       Impact factor: 6.961

View more
  2 in total

Review 1.  Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis.

Authors:  Vasiliy Ivanovich Reshetnyak
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

2.  Refractory pruritus in primary biliary cirrhosis.

Authors:  Nuno Cercas Pinheiro; Rui Tato Marinho; Fernando Ramalho; José Velosa
Journal:  BMJ Case Rep       Date:  2013-11-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.